Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
Activities of HMR 3787 and RU 64399 were compared to those of three macrolides, telithromycin, and clindamycin against 175 Streptococcus pneumoniae isolates and 121 Streptococcus pyogenes isolates. HMR3787 and telithromycin were the most active compounds tested against pneumococci. Telithromycin and RU 64399 were equally active against macrolide-susceptible (MICs, 0.008 to 0.06 microg/ml) and -resistant S. pyogenes isolates, but HMR 3787 had lower MICs for ermB strains.
Nagai
K
K
Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Davies
T A
TA
Ednie
L M
LM
Bryskier
A
A
Palavecino
E
E
Jacobs
M R
MR
Appelbaum
P C
PC
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D004351:Drug Resistance; D004917:Erythromycin / Q000627:therapeutic use; D048628:Ketolides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013297:Streptococcus pyogenes / Q000187:drug effects*
D000900:Anti-Bacterial Agents; C439346:HMR 3787; D048628:Ketolides; D018942:Macrolides; C444466:RU 64399; D002981:Clindamycin; D004917:Erythromycin; D017963:Azithromycin; D017291:Clarithromycin; C106791:telithromycin